D
Douglas A. Arenberg
Researcher at University of Michigan
Publications - 142
Citations - 11086
Douglas A. Arenberg is an academic researcher from University of Michigan. The author has contributed to research in topics: Lung cancer & Angiogenesis. The author has an hindex of 49, co-authored 128 publications receiving 10125 citations. Previous affiliations of Douglas A. Arenberg include University of Nebraska Medical Center.
Papers
More filters
Journal ArticleDOI
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Robert M. Strieter,Peter J. Polverini,Steven L. Kunkel,Douglas A. Arenberg,Marie D. Burdick,James J. Kasper,Judith Dzuiba,Jo Van Damme,Alfred Walz,David Marriott,Sham Yuen Chan,Steven Roczniak,Shanafelt Armen B +12 more
TL;DR: A functional role of the ELR motif is suggested in determining the angiogenic or angiostatic potential of CXC chemokines, supporting the hypothesis that the net biological balance between angiogenicity and angiOSTatic CXCs may play an important role in regulating overall angiogenesis.
Journal ArticleDOI
CXC Chemokines in Angiogenesis
John A. Belperio,Michael P. Keane,Douglas A. Arenberg,Christina L. Addison,Jan E. Ehlert,Marie D. Burdick,Robert M. Strieter +6 more
TL;DR: In contrast, members that are inducible by interferons and lack the ELR motif (ELR−) are potent inhibitors of angiogenesis, a difference in angiogenic activity that may impact on the pathogenesis of a variety of disorders.
Journal ArticleDOI
Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.
Douglas A. Arenberg,Steven L. Kunkel,Peter J. Polverini,Mary C. Glass,Marie D. Burdick,Robert M. Strieter +5 more
TL;DR: The notion that IL-8 plays a significant role in mediating angiogenic activity during tumorigenesis of human NSCLC, thereby offering a potential target for immunotherapy against solid tumors, is supported.
Journal ArticleDOI
Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases.
Douglas A. Arenberg,Steven L. Kunkel,Peter J. Polverini,Susan B. Morris,Marie D. Burdick,Mary C. Glass,Dennis T. Taub,Mark D. Iannettoni,Richard I. Whyte,Robert M. Strieter +9 more
TL;DR: The notion that tumor-derived IP-10 is an important endogenous angiostatic factor in NSCLC is supported, as a potent angiOSTatic factor that regulates non-small cell lung cancer-derived angiogenesis, tumor growth, and spontaneous metastasis.
Journal ArticleDOI
Treatment of Stage III Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Nithya Ramnath,Thomas J. Dilling,Loren J. Harris,Anthony W. Kim,Gaetane Michaud,Alex Balekian,Rebecca L. Diekemper,Frank C. Detterbeck,Douglas A. Arenberg +8 more
TL;DR: Multimodality therapy is preferable in most subsets of patients with stage III lung cancer, and routine platinum-based adjuvant chemotherapy following complete resection of stage IIIA lung cancer encountered unexpectedly at surgery is supported.